High-frequency ultrasound assessment of vulvar lichen sclerosus treated with photodynamic therapy

Wang, Yukun; Hao, Jianchun; Liu, Jie

doi:10.1016/j.pdpdt.2023.103277

Cited by 7 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, there is disagreement regarding the clinical and histological improvements [70]. Some instances showed healing of superficial erosions and improvement of clinical symptoms after PDT, while others did not show any clinical changes [71,72]. However, other researchers have reported an increased occurrence of apoptosis and the eradication of persistent inflammation [73,74].…”

Section: Vls: Current Treatment Paradigmmentioning

confidence: 99%

Vulvar Lichen Sclerosus: Navigating Sex Hormone Dynamics and Pioneering Personalized Treatment Paradigm

Popa,

Dumitrascu,

Petca

et al. 2024

JPM

View full text Add to dashboard Cite

Vulvar lichen sclerosus (VLS) is a frequently overlooked inflammatory disorder affecting the skin and mucous membranes of the vulva. With a propensity for atrophy, severe scarring, functional impairment, and malignant evolution, VLS is a disease that recurs frequently; early diagnosis, rapid treatment, and ongoing patient follow-up are essential. Potent topical corticosteroids (TCSs) are now widely recognized as the most effective treatment for achieving remission in VLS, but considering the potential complications of long-term treatment with potent TCSs, understanding the evolution of VLS during puberty becomes particularly crucial in determining the necessity for aggressive or more conservative therapeutic interventions. Emerging treatments, including PRP (platelet-rich plasma), stem cell therapy, and energy-based lasers like fractional CO2 and Nd-YAG, are being investigated to identify more effective VLS treatments than ultrapotent topical corticosteroids. However, more research is needed to assess the efficacy and safety of these new medicines. Topical clobetasol 0.05% ointment daily for 4–12 weeks is the gold standard for treating VLS. This article is a narrative review of the English-language medical literature from 2017 to November 2023, following three main sections concerning VLS: studies of the evolution amid pubertal hormonal changes; studies of the outcomes of personalized conventional therapies; and studies addressing the spectrum of innovative modalities for VLS.

show abstract